Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, ASND, BBIO, GPCR, TGTX, and represent 21.16% of Exome Asset Management's stock portfolio.
- Added to shares of these 10 stocks: GPCR (+$5.3M), ALGN, GILD, GERN, BNTX, BMY, VRDN, ASND, BPMC, GKOS.
- Started 30 new stock positions in ETNB, LXEO, LEGN, EWTX, BNTX, ALGN, SRRK, BMY, GERN, MRSN.
- Reduced shares in these 10 stocks: SRPT (-$5.2M), BGNE, CRBP, TVTX, MDGL, AVDL, DXCM, AUTL, MRUS, MASI.
- Sold out of its positions in ABCL, ATEC, ARVN, AUTL, CABA, CRBP, DXCM, ELEV, FULC, HLVX. IMAB, MDGL, MASI, PMVP, QTTB, SGMT, SRPT, TVTX, ZLAB, BHVN, AVDL, MRUS, WVE.
- Exome Asset Management was a net buyer of stock by $29M.
- Exome Asset Management has $148M in assets under management (AUM), dropping by 31.71%.
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 59 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 6.3 | $9.3M | +7% | 10k | 885.94 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 4.4 | $6.5M | +119% | 44k | 149.31 |
|
| Bridgebio Pharma (BBIO) | 3.6 | $5.4M | +167% | 211k | 25.46 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.6 | $5.3M | NEW | 120k | 43.89 |
|
| Tg Therapeutics (TGTX) | 3.3 | $4.9M | -17% | 208k | 23.39 |
|
| Align Technology (ALGN) | 3.2 | $4.8M | NEW | 19k | 254.32 |
|
| Cigna Corp (CI) | 2.9 | $4.2M | 12k | 346.44 |
|
|
| Gilead Sciences (GILD) | 2.8 | $4.2M | NEW | 50k | 83.84 |
|
| Geron Corporation (GERN) | 2.8 | $4.1M | NEW | 905k | 4.54 |
|
| Biontech Se Sponsored Ads (BNTX) | 2.8 | $4.1M | NEW | 35k | 118.77 |
|
| Bristol Myers Squibb (BMY) | 2.7 | $4.0M | NEW | 78k | 51.74 |
|
| Miragen Therapeutics (VRDN) | 2.7 | $4.0M | NEW | 174k | 22.75 |
|
| Intuitive Surgical Com New (ISRG) | 2.5 | $3.6M | +16% | 7.4k | 491.27 |
|
| Beigene Sponsored Adr (BGNE) | 2.3 | $3.4M | -53% | 15k | 224.51 |
|
| Blueprint Medicines (BPMC) | 2.3 | $3.4M | NEW | 37k | 92.50 |
|
| Glaukos (GKOS) | 2.3 | $3.4M | NEW | 26k | 130.28 |
|
| Springworks Therapeutics (SWTX) | 2.2 | $3.2M | NEW | 101k | 32.04 |
|
| Disc Medicine (IRON) | 2.1 | $3.2M | +5% | 65k | 49.14 |
|
| Cytokinetics Com New (CYTK) | 2.1 | $3.1M | NEW | 59k | 52.80 |
|
| Agios Pharmaceuticals (AGIO) | 2.0 | $2.9M | NEW | 66k | 44.43 |
|
| Relay Therapeutics (RLAY) | 2.0 | $2.9M | NEW | 415k | 7.08 |
|
| Apellis Pharmaceuticals (APLS) | 2.0 | $2.9M | +114% | 100k | 28.84 |
|
| Dr Reddys Labs Adr (RDY) | 1.9 | $2.9M | 36k | 79.45 |
|
|
| Natera (NTRA) | 1.9 | $2.9M | +20% | 23k | 126.95 |
|
| Biogen Idec (BIIB) | 1.7 | $2.6M | NEW | 13k | 193.21 |
|
| Insmed Com Par $.01 (INSM) | 1.7 | $2.5M | -40% | 34k | 73.00 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.5 | $2.3M | NEW | 47k | 48.73 |
|
| Mersana Therapeutics (MRSN) | 1.5 | $2.2M | NEW | 1.2M | 1.89 |
|
| 89bio (ETNB) | 1.5 | $2.2M | NEW | 301k | 7.40 |
|
| Akero Therapeutics (AKRO) | 1.5 | $2.2M | NEW | 77k | 28.69 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.5 | $2.2M | -49% | 138k | 15.99 |
|
| Stoke Therapeutics (STOK) | 1.5 | $2.2M | NEW | 177k | 12.29 |
|
| Amgen (AMGN) | 1.5 | $2.2M | -43% | 6.7k | 322.21 |
|
| Guardant Health (GH) | 1.4 | $2.1M | +13% | 90k | 22.94 |
|
| Nuvalent Inc-a (NUVL) | 1.4 | $2.0M | NEW | 20k | 102.30 |
|
| Revance Therapeutics (RVNC) | 1.2 | $1.8M | NEW | 348k | 5.19 |
|
| Kura Oncology (KURA) | 1.2 | $1.8M | -31% | 90k | 19.54 |
|
| Rezolute Com New (RZLT) | 1.2 | $1.7M | +24% | 352k | 4.85 |
|
| Pliant Therapeutics (PLRX) | 1.1 | $1.7M | +20% | 150k | 11.21 |
|
| Edgewise Therapeutics (EWTX) | 1.1 | $1.6M | NEW | 60k | 26.69 |
|
| Karyopharm Therapeutics Note 3.000%10/1 | 1.0 | $1.5M | NEW | 2.0M | 0.76 |
|
| Staar Surgical Com Par $0.01 (STAA) | 1.0 | $1.5M | NEW | 41k | 37.15 |
|
| Tarsus Pharmaceuticals (TARS) | 1.0 | $1.5M | NEW | 46k | 32.89 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.0 | $1.5M | NEW | 197k | 7.60 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.8 | $1.1M | NEW | 133k | 8.38 |
|
| Tectonic Therapeutic (TECX) | 0.7 | $1.1M | +12% | 36k | 30.30 |
|
| Alvotech Ordinary Shares (ALVO) | 0.7 | $1.1M | -8% | 90k | 11.90 |
|
| Quanterix Ord (QTRX) | 0.6 | $953k | +23% | 74k | 12.96 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.6 | $939k | 22k | 43.27 |
|
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.6 | $817k | NEW | 117k | 7.00 |
|
| Lexeo Therapeutics (LXEO) | 0.5 | $797k | NEW | 88k | 9.04 |
|
| Vyne Therapeutics (VYNE) | 0.4 | $665k | 353k | 1.88 |
|
|
| Syros Pharmaceuticals Com New (SYRS) | 0.4 | $642k | +87% | 299k | 2.15 |
|
| Adagene Ads (ADAG) | 0.4 | $583k | +74% | 263k | 2.22 |
|
| Gossamer Bio (GOSS) | 0.3 | $462k | -58% | 469k | 0.99 |
|
| Aprea Therapeutics Com New (APRE) | 0.3 | $377k | 137k | 2.75 |
|
|
| Procaps Group Sa SHS (PROC) | 0.2 | $281k | 127k | 2.21 |
|
|
| Leap Therapeutics Com New (LPTX) | 0.2 | $264k | NEW | 103k | 2.57 |
|
| Pacific Biosciences of California (PACB) | 0.1 | $128k | 75k | 1.70 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2024 Q3 amended filed Dec. 13, 2024
- Exome Asset Management 2024 Q2 restated filed Oct. 3, 2024
- Exome Asset Management 2024 Q2 filed Aug. 14, 2024
- Exome Asset Management 2024 Q1 filed May 15, 2024
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024